Passage Bio, Inc.

0.91 USD
-0.00 (-0.14%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Passage Bio, Inc. stock is down -25.52% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 June’s closed higher than May.

About Passage Bio, Inc.

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysososomal acid beta-galactosidase for infantile GM1. The company also develops PBML04 for the treatment of metachromatic leukodystrophy.